Dynavax Technologies Corporation (NASDAQ:DVAX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday.

According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “

Several other equities research analysts have also recently weighed in on DVAX. Royal Bank Of Canada increased their target price on shares of Dynavax Technologies Corporation from $6.00 to $7.00 and gave the company a “sector perform” rating in a research note on Tuesday, May 9th. ValuEngine cut shares of Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. William Blair reissued an “outperform” rating on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Cowen and Company reissued an “outperform” rating and issued a $45.00 price target on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Finally, J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $6.00 to $27.00 in a research report on Monday, July 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $23.67.

Shares of Dynavax Technologies Corporation (DVAX) traded down 2.65% during mid-day trading on Friday, reaching $16.55. The company had a trading volume of 5,976,168 shares. The company’s 50-day moving average price is $9.75 and its 200-day moving average price is $6.44. Dynavax Technologies Corporation has a 52-week low of $3.20 and a 52-week high of $17.50. The company’s market capitalization is $906.08 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 101.98%. The business had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.15 million. During the same quarter last year, the company earned ($0.75) earnings per share. On average, analysts forecast that Dynavax Technologies Corporation will post ($1.72) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/08/06/dynavax-technologies-corporation-dvax-upgraded-at-zacks-investment-research.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. GMT Capital Corp raised its position in Dynavax Technologies Corporation by 231.5% in the first quarter. GMT Capital Corp now owns 2,344,500 shares of the biopharmaceutical company’s stock valued at $13,950,000 after buying an additional 1,637,300 shares during the period. Vanguard Group Inc. raised its stake in Dynavax Technologies Corporation by 14.4% in the first quarter. Vanguard Group Inc. now owns 1,825,662 shares of the biopharmaceutical company’s stock valued at $10,864,000 after buying an additional 230,373 shares during the last quarter. Blair William & Co. IL raised its stake in Dynavax Technologies Corporation by 1.8% in the first quarter. Blair William & Co. IL now owns 1,346,494 shares of the biopharmaceutical company’s stock valued at $6,059,000 after buying an additional 23,701 shares during the last quarter. Kornitzer Capital Management Inc. KS raised its stake in Dynavax Technologies Corporation by 4.0% in the second quarter. Kornitzer Capital Management Inc. KS now owns 1,142,360 shares of the biopharmaceutical company’s stock valued at $11,024,000 after buying an additional 43,850 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Dynavax Technologies Corporation during the first quarter valued at $4,323,000. 54.94% of the stock is owned by hedge funds and other institutional investors.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Get a free copy of the Zacks research report on Dynavax Technologies Corporation (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.